CKD Bio Corp. (063160.KS)
KRW 23350.0
(-0.21%)
KRW 23350.0
(-0.21%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 69.08 Billion KRW | -12.0% |
| 2022 | 78.5 Billion KRW | 11.59% |
| 2021 | 70.35 Billion KRW | 19.02% |
| 2020 | 59.11 Billion KRW | 88.03% |
| 2019 | 31.43 Billion KRW | 10.69% |
| 2018 | 28.4 Billion KRW | -14.56% |
| 2017 | 33.24 Billion KRW | -13.9% |
| 2016 | 38.61 Billion KRW | 10.08% |
| 2015 | 35.07 Billion KRW | 13.29% |
| 2014 | 30.95 Billion KRW | -16.62% |
| 2013 | 37.13 Billion KRW | 16.5% |
| 2012 | 31.87 Billion KRW | 5.87% |
| 2011 | 30.1 Billion KRW | 37.86% |
| 2010 | 21.83 Billion KRW | -4.1% |
| 2009 | 22.77 Billion KRW | -10.39% |
| 2008 | 25.41 Billion KRW | 29.28% |
| 2007 | 19.65 Billion KRW | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 67.24 Billion KRW | -4.02% |
| 2024 Q1 | 70.05 Billion KRW | 1.41% |
| 2023 Q2 | 71.49 Billion KRW | -0.0% |
| 2023 Q3 | 71.93 Billion KRW | 0.62% |
| 2023 Q4 | 69.08 Billion KRW | -3.96% |
| 2023 FY | 69.08 Billion KRW | -12.0% |
| 2023 Q1 | 71.49 Billion KRW | -8.94% |
| 2022 Q3 | 78.35 Billion KRW | 14.27% |
| 2022 Q2 | 68.57 Billion KRW | 6.94% |
| 2022 FY | 78.5 Billion KRW | 11.59% |
| 2022 Q1 | 64.12 Billion KRW | -8.86% |
| 2022 Q4 | 78.5 Billion KRW | 0.19% |
| 2021 FY | 70.35 Billion KRW | 19.02% |
| 2021 Q2 | 62.82 Billion KRW | 1.7% |
| 2021 Q1 | 61.78 Billion KRW | 4.51% |
| 2021 Q4 | 70.35 Billion KRW | 12.43% |
| 2021 Q3 | 62.57 Billion KRW | -0.4% |
| 2020 Q4 | 59.11 Billion KRW | 16.33% |
| 2020 Q1 | 37.15 Billion KRW | 18.18% |
| 2020 Q2 | 40.75 Billion KRW | 9.7% |
| 2020 Q3 | 50.81 Billion KRW | 24.67% |
| 2020 FY | 59.11 Billion KRW | 88.03% |
| 2019 Q4 | 31.43 Billion KRW | 0.17% |
| 2019 FY | 31.43 Billion KRW | 10.69% |
| 2019 Q1 | 29.57 Billion KRW | 4.12% |
| 2019 Q2 | 31.27 Billion KRW | 5.76% |
| 2019 Q3 | 31.38 Billion KRW | 0.35% |
| 2018 FY | 28.4 Billion KRW | -14.56% |
| 2018 Q4 | 28.4 Billion KRW | -0.93% |
| 2018 Q3 | 28.66 Billion KRW | -3.7% |
| 2018 Q2 | 29.77 Billion KRW | -3.79% |
| 2018 Q1 | 30.94 Billion KRW | -6.92% |
| 2017 Q4 | 33.24 Billion KRW | -5.7% |
| 2017 FY | 33.24 Billion KRW | -13.9% |
| 2017 Q3 | 35.25 Billion KRW | -0.67% |
| 2017 Q2 | 35.49 Billion KRW | -2.92% |
| 2017 Q1 | 36.56 Billion KRW | -5.31% |
| 2016 Q2 | 40.26 Billion KRW | 9.79% |
| 2016 Q3 | 39.76 Billion KRW | -1.25% |
| 2016 FY | 38.61 Billion KRW | 10.08% |
| 2016 Q4 | 38.61 Billion KRW | -2.9% |
| 2016 Q1 | 36.67 Billion KRW | 4.57% |
| 2015 Q1 | 32.66 Billion KRW | 5.53% |
| 2015 Q3 | 33.73 Billion KRW | 4.87% |
| 2015 Q2 | 32.16 Billion KRW | -1.55% |
| 2015 Q4 | 35.07 Billion KRW | 3.98% |
| 2015 FY | 35.07 Billion KRW | 13.29% |
| 2014 FY | 30.95 Billion KRW | -16.62% |
| 2014 Q4 | 30.95 Billion KRW | 0.82% |
| 2014 Q3 | 30.7 Billion KRW | -4.84% |
| 2014 Q1 | 34.42 Billion KRW | -7.29% |
| 2014 Q2 | 32.26 Billion KRW | -6.26% |
| 2013 Q4 | 37.13 Billion KRW | 13.64% |
| 2013 FY | 37.13 Billion KRW | 16.5% |
| 2013 Q1 | 30.61 Billion KRW | -3.95% |
| 2013 Q2 | 31.45 Billion KRW | 2.73% |
| 2013 Q3 | 32.67 Billion KRW | 3.89% |
| 2012 Q2 | 30.48 Billion KRW | -5.58% |
| 2012 Q1 | 32.28 Billion KRW | 7.24% |
| 2012 Q3 | 32.9 Billion KRW | 7.96% |
| 2012 FY | 31.87 Billion KRW | 5.87% |
| 2012 Q4 | 31.87 Billion KRW | -3.15% |
| 2011 FY | 30.1 Billion KRW | 37.86% |
| 2011 Q4 | 30.1 Billion KRW | 0.66% |
| 2011 Q3 | 29.9 Billion KRW | 8.76% |
| 2011 Q2 | 27.49 Billion KRW | 17.65% |
| 2011 Q1 | 23.37 Billion KRW | 7.02% |
| 2010 Q1 | 18.84 Billion KRW | -17.23% |
| 2010 Q3 | 20.44 Billion KRW | 39.66% |
| 2010 Q4 | 21.83 Billion KRW | 6.8% |
| 2010 FY | 21.83 Billion KRW | -4.1% |
| 2010 Q2 | 14.64 Billion KRW | -22.31% |
| 2009 Q4 | 22.77 Billion KRW | -12.75% |
| 2009 FY | 22.77 Billion KRW | -10.39% |
| 2009 Q3 | 26.09 Billion KRW | 1.5% |
| 2009 Q2 | 25.71 Billion KRW | -4.43% |
| 2009 Q1 | 26.9 Billion KRW | 5.87% |
| 2008 Q1 | 21.18 Billion KRW | 7.79% |
| 2008 Q2 | 22.17 Billion KRW | 4.64% |
| 2008 Q3 | 21.51 Billion KRW | -2.95% |
| 2008 Q4 | 25.41 Billion KRW | 18.1% |
| 2008 FY | 25.41 Billion KRW | 29.28% |
| 2007 Q2 | 19.21 Billion KRW | 12.62% |
| 2007 FY | 19.65 Billion KRW | 0.0% |
| 2007 Q1 | 17.05 Billion KRW | 0.0% |
| 2007 Q4 | 19.65 Billion KRW | -6.92% |
| 2007 Q3 | 21.11 Billion KRW | 9.92% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Dongwha Pharm.Co.,Ltd | 70.69 Billion KRW | 2.284% |
| Yuhan Corporation | 284.75 Billion KRW | 75.74% |
| Yuhan Corporation | 284.75 Billion KRW | 75.74% |
| Yuyu Pharma, Inc. | 44.15 Billion KRW | -56.464% |
| Yuyu Pharma, Inc. | 44.15 Billion KRW | -56.464% |
| Yuyu Pharma, Inc. | 44.15 Billion KRW | -56.464% |
| Ildong Holdings Co., Ltd. | 91.16 Billion KRW | 24.224% |
| Samil Pharmaceutical Co.,Ltd | 32.51 Billion KRW | -112.486% |
| Dong-A Socio Holdings Co., Ltd. | 117.85 Billion KRW | 41.382% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | 34.884% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | 34.884% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | 34.884% |
| SAMSUNG PHARM. Co., LTD. | 16.25 Billion KRW | -324.894% |
| Chong Kun Dang Holdings Corp. | 194.76 Billion KRW | 64.53% |
| Dong Sung Bio Pharm.Co.,Ltd. | 19.47 Billion KRW | -254.685% |
| HANDOK Inc. | 94.46 Billion KRW | 26.87% |
| Jeil Pharma Holdings Inc | 125.28 Billion KRW | 44.858% |
| Kukje Pharma Co., Ltd. | 21.24 Billion KRW | -225.198% |
| Bukwang Pharmaceutical Co., Ltd. | 56.83 Billion KRW | -21.555% |
| Aprogen pharmaceuticals,Inc. | 48.12 Billion KRW | -43.538% |
| Ilsung Pharmaceuticals Co., Ltd. | 31.24 Billion KRW | -121.128% |
| Daewon Pharmaceutical Co., Ltd. | 105.07 Billion KRW | 34.256% |
| Yungjin Pharm. Co., Ltd. | 61.98 Billion KRW | -11.447% |
| Boryung Corporation | 189.8 Billion KRW | 63.604% |
| Hyundai Pharmaceutical Co., Ltd. | 26.99 Billion KRW | -155.879% |
| Samjin Pharmaceuticals Co., Ltd. | 79.6 Billion KRW | 13.216% |
| Ilyang Pharmaceutical Co.,Ltd | 61.72 Billion KRW | -11.92% |
| Ilyang Pharmaceutical Co.,Ltd | 61.72 Billion KRW | -11.92% |
| Suheung Co., Ltd. | 259.84 Billion KRW | 73.414% |
| Kwang Dong Pharmaceutical Co., Ltd. | 188.64 Billion KRW | 63.379% |
| Hanall Biopharma Co.,Ltd | 32.38 Billion KRW | -113.321% |
| Whan In Pharm Co.,Ltd. | 54.05 Billion KRW | -27.793% |
| MYUNGMOON Pharm co.,Ltd | 30.28 Billion KRW | -128.143% |
| Shin Poong Pharm.Co.,Ltd. | 53.92 Billion KRW | -28.112% |
| Shin Poong Pharm.Co.,Ltd. | 53.92 Billion KRW | -28.112% |
| Korea United Pharm Inc. | 49.14 Billion KRW | -40.577% |
| Daewoong pharmaceutical Co.,Ltd | 241.54 Billion KRW | 71.4% |
| JW Holdings Corporation | 147.58 Billion KRW | 53.193% |
| REYON Pharmaceutical Co., Ltd. | 35.17 Billion KRW | -96.388% |
| Hanmi Pharm. Co., Ltd. | 288.81 Billion KRW | 76.081% |
| Dong-A ST Co., Ltd. | 116.31 Billion KRW | 40.607% |
| Chong Kun Dang Pharmaceutical Corp. | 261.43 Billion KRW | 73.575% |
| JW Lifescience Corporation | 23.39 Billion KRW | -195.241% |
| Ildong Pharmaceutical Co., Ltd. | 84.62 Billion KRW | 18.365% |
| Jeil Pharmaceutical Co.,Ltd | 109.76 Billion KRW | 37.065% |
| Hana Pharm Co., Ltd. | 48.34 Billion KRW | -42.887% |